Abstract

BackgroundIt has been suggested that Skogholt’s disease is a new neurological disease entity. The disease, confined to a family line in Hedmark county, Norway, usually affects both the brain and peripheral nerves. Typical findings are white matter lesions in the brain, myelin damage in peripheral nerves, and discolored cerebrospinal fluid with high concentrations of protein, copper, and iron. Little is known about the natural progression of the disease and its underlying cause, but the high level of copper and iron in the cerebrospinal fluid may cause or exacerbate inflammation in the central nervous system. MethodsThe present clinical study further explores the disease progression with clinical chemistry analyses and mass spectrometry of blood and cerebrospinal fluid (CSF) from patients and controls. Findings are corroborated with cognitive assessments. ResultsPathological changes in CSF with low amyloid-β42 and high levels of tau proteins, total protein, copper, and iron, were discovered among Skogholt patients. The Montreal Cognitive Assessment identified 36 % of the patients as below normal range, while most patients performed slower than the norm mean time on the Trail Making Test. Mini-Mental Status Examination disclosed only minor deviations. ConclusionThe findings in the present study strengthen our initial suggestion that Skogholt’s disease most likely is a new neurological disorder and provide new clues to its cause: The disease may belong to the family of neurodegenerative disorders termed tauopathies. The increased level of copper and iron may contribute to neuroinflammation as these metals also have been associated with other neurodegenerative disorders. Although the causes of neurodegenerative disorders are currently largely unknown, studies on rare disease entities, such as the present one, may increase the understanding of neurodegeneration in general.

Highlights

  • Neurodegenerative disorders such as Alzheimer’s (AD) and Parkin­ son’s disease make up a substantial part of the neurological global burden of disease [1]

  • The mean cerebrospinal fluid (CSF) levels of total protein and albumin in Skogholt pa­ tients was elevated by factors of 3.5 and 3.4 respectively, compared to controls

  • Consid­ ering common biomarkers of neurodegeneration, the patients are characterized by substantially elevated levels of total tau (T-tau) and P-tau proteins in the CSF, and the values for Aβ42 are modestly decreased compared with controls and established cut-off limits [13]

Read more

Summary

Introduction

Neurodegenerative disorders such as Alzheimer’s (AD) and Parkin­ son’s disease make up a substantial part of the neurological global burden of disease [1]. A local community physician in the southeastern region of Norway, Jon Skogholt, identified in the 1980s a family line with several cases of what appeared to be a new dys-myelinating disorder [6], later referred to as Skogholt’s disease [7]. The condition affects both the central and peripheral nervous system. Typical findings are white matter lesions in the brain, myelin damage in peripheral nerves, and discolored ce­ rebrospinal fluid with high concentrations of protein, copper, and iron. The causes of neurodegenerative disorders are currently largely unknown, studies on rare disease entities, such as the present one, may increase the understanding of neurodegeneration in general

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call